Pipeline

Current Clinical Trials

Advanced Melanoma

TRIAL

KEYNOTE-695
Multicenter Phase II, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (TAVO, pIL-12) Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment 

OBJECTIVE

Evaluate the efficacy of the combination of KEYTRUDA®, a registered trademark of Merck Sharp & Dohme Corp., and TAVO in advanced metastatic melanoma patients that are progressing on pembrolizumab or nivolumab.

Status: RECRUITINGLEARN MORE

ClinicalTrials.gov Identifier: NCT03132675

TRIAL

OMS-102
Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation

OBJECTIVE

Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma†.

†This is a collaboration with University of California, San Francisco

Status: ENROLLMENT COMPLETELEARN MORE

ClinicalTrials.gov Identifier: NCT02493361

 

Triple Negative Breast Cancer

TRIAL

OMS-140
Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer (TNBC)

OBJECTIVE

Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer.

Status: ENROLLMENT COMPLETELEARN MORE

ClinicalTrials.gov Identifier: NCT02531425

OMS-141/KEYNOTE-890
Intratumoral Delivery of Plasmid IL-12  and Pembrolizumab in Patients with Inoperable Locally Advanced or Metastatic TNBC

OBJECTIVE

Evaluate the combination of intratumoral pIL-12  with pembrolizumab in TNBC patients with inoperable locally advanced or metastatic TNBC who have progressed on more than one line of prior therapy.

Status: RECRUITINGLEARN MORE

ClinicalTrials.gov Identifier: NCT03567720

 

 

Squamous Cell Carcinoma of the Head and Neck

TRIAL

OMS-131
This phase II trial studies how well tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by surgery.

OBJECTIVE

Determine whether the combination of tavokinogene telseplasmid (tavo)-electroporation (EP), pembrolizumab, and epacadostat increases the best overall response rate (BORR) in squamous cell carcinoma of the head and neck (SCCHN) compared with historical data for pembrolizumab monotherapy.

Status: RECRUITINGLEARN MORE

ClinicalTrials.gov Identifier: NCT03823131